Company
Novocure
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
27
As lead sponsor, any status
Adverse event reports
282
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
NVCR
Nasdaq · NovoCure Ltd
Public float
$995M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$655M
Fiscal year ending Dec 31, 2025
Net income
-$136M
Fiscal year ending Dec 31, 2025
R&D spending
$225M
Fiscal year ending Dec 31, 2025
Cash
$96.7M
As of Sep 30, 2026
Long-term debt
$195M
As of Dec 31, 2025
Shares outstanding
116.9M
As of Oct 23, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | $3.7M | $100.0M | – |
| 2024 | – | $4.2M | $96.9M | – |
| 2023 | – | $4.4M | – | – |
| 2022 | – | $5.2M | – | – |
| 2021 | – | $4.5M | – | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
- Optune PaxBreakthroughPMA
P250034 · Decided Feb 11, 2026 · 180 days after receipt
Device type: Low Electric Field Generator for Pancreatic Cancer Treatment (SHC) · General & Plastic Surgery
- Optune LuaPMA
P230042 · Decided Oct 15, 2024 · 305 days after receipt
Device type: Electrical tumor treatment fields for non-small cell lung cancer (SDA) · Anesthesiology & Respiratory
- OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM)PMA supplement
P100034-S013 · Decided Oct 5, 2015 · 178 days after receipt · Panel Track
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCPivotal-lookingRecruiting
NCT06216301 · 734 participants (planned) · Start Jul 31, 2024 · Primary completion Oct 2028
Device: NovoTTF-200T · For: Metastatic Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Fullerton, California · 107 sites in all
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaPivotal-lookingActive, not recruiting
NCT06556563 · 741 participants (planned) · Start Feb 3, 2025 · Primary completion Apr 2029
Device: Optune® device · For: Glioblastoma
Sites: Phoenix, Arizona; Los Angeles, California; Newport Beach, California · 102 sites in all
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBMPivotal-lookingCompleted
NCT04471844 · 981 participants · Start Dec 8, 2020 · Primary completion Feb 19, 2026
Device: Optune® · For: Glioblastoma Multiforme
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 130 sites in all
24 more trials with a free account
Reports received
282
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
280
99% of reports
Death reports
2
0.7% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 1 | 0 | 0 |
| Jan 24 | 0 | 4 | 0 | 0 |
| Feb 24 | 0 | 4 | 0 | 0 |
| Mar 24 | 0 | 5 | 0 | 0 |
| Apr 24 | 0 | 7 | 0 | 0 |
| May 24 | 0 | 8 | 0 | 0 |
| Jun 24 | 0 | 13 | 0 | 0 |
| Jul 24 | 0 | 15 | 0 | 0 |
| Aug 24 | 0 | 23 | 0 | 0 |
| Sep 24 | 0 | 16 | 0 | 0 |
| Oct 24 | 0 | 22 | 0 | 0 |
| Nov 24 | 0 | 20 | 0 | 0 |
| Dec 24 | 0 | 21 | 0 | 0 |
| Jan 25 | 0 | 20 | 0 | 0 |
| Feb 25 | 0 | 19 | 0 | 0 |
| Mar 25 | 0 | 23 | 0 | 0 |
| Apr 25 | 1 | 26 | 0 | 0 |
| May 25 | 0 | 19 | 0 | 0 |
| Jun 25 | 0 | 20 | 0 | 0 |
| Jul 25 | 0 | 20 | 0 | 0 |
| Aug 25 | 0 | 19 | 0 | 0 |
| Sep 25 | 0 | 13 | 0 | 0 |
| Oct 25 | 0 | 25 | 0 | 0 |
| Nov 25 | 0 | 17 | 0 | 0 |
| Dec 25 | 0 | 33 | 0 | 0 |
| Jan 26 | 0 | 13 | 0 | 0 |
| Feb 26 | 0 | 17 | 0 | 0 |
| Mar 26 | 0 | 20 | 0 | 0 |
| Apr 26 | 0 | 11 | 0 | 0 |
| May 26 | 0 | 23 | 0 | 0 |
| Jun 26 | 0 | 42 | 1 | 0 |
| Jul 26 | 0 | 28 | 0 | 0 |
| Aug 26 | 0 | 22 | 0 | 0 |
| Sep 26 | 0 | 31 | 1 | 0 |
| Oct 26 | 0 | 23 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
1 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- OPTUNE GIO254
2 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.